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Mitochondrial DNA Mutations, Apoptosis, and the
Misfolded Protein Response
JUSTIN L. MOTT,* DEKUI ZHANG,* and HANS PETER ZASSENHAUS

ABSTRACT
Studies of transgenic mice with accelerated accumulation of mtDNA mutations specifically
in the heart lead us to propose that apoptotic signaling and cell death is central to the pathogenesis of mtDNA mutations in aging. It is the cellular response to that apoptotic signaling
and the organ’s compensatory response to a loss of cells that specify the phenotype of an accumulation of mtDNA mutations. In the heart, cardiomyocytes induce a vigorous anti-apoptotic, pro-survival response to counteract mitochondrial apoptotic signaling. The heart up-regulates contractility of remaining myocytes in order to maintain cardiac output. We hypothesize
that mutant mitochondrial proteins originate apoptotic signaling by interacting with proteins
already in place in the mitochondrial outer membrane that regulate apoptosis, for example
the pro-apoptotic protein Bak. Since it is unlikely that all mutant mitochondrial proteins have
the necessary structure and localization within the inner membrane to activate Bak appropriately, only a small fraction of an age-associated burden of mtDNA mutations may be pathogenic. In this model, reactive oxygen species generated by mitochondrial respiration drive
the formation of mtDNA mutations, but are not the primary mechanism for their pathogenicity.

M

DNA (mtDNA) mutations
accumulate with age and disease.1 These
sporadic mutations randomly affect the mitochondrial genome, and thus a mutation at any
particular nucleotide position is rare. Even with
advanced age, the frequency of mutations generally does not exceed 1% in otherwise normal
individuals.2 Thus, for these mutations to cause
disease or senescence, the cell needs to be very
sensitive to mtDNA mutations. Recent evidence suggests that the burden of point mutaITOCHONDRIAL

tions in mtDNA may be higher than previously
thought,3 so that estimates extrapolate to an average of three point mutations per genome in
the aged brain.4 Still, given the random distribution of those mutations and the multiple
copies of mtDNA per mitochondrion, their effect on respiratory function would be expected
to be slight.
Despite their low frequency, mtDNA mutations are still more common than nuclear DNA
mutations. Because of the compact nature of

*Each of these authors contributed equally to this manuscript.
Department of Molecular Microbiology and Immunology, St. Louis University Health Science Center, St. Louis,
Missouri.

216

217

MITOCHONDRIAL DNA MUTATIONS AND APOPTOSIS

the mitochondrial genome, these mutations are
also more likely to affect a coding region. Due
to heterogeneity, the mutation level may be
higher in a given cell than the overall average
of the tissue.5 At the next level of compartmentalization, the mitochondrion itself will
have an even higher proportion of mutant
genomes. Consider a cell that has only a single
mutation on a background of maybe 1000 wildtype mitochondrial genomes. The tissue mutation level may be undetectable, the cellular mutation level would be 1/1000 genomes. But the
level of the mutation in the affected mitochondrion would be 10–50% (given two to 10
genomes in this prototypical mitochondrion).
If mtDNA mutations contribute to disease, the
signaling mechanism must sense the high proportion of mutation within a mitochondrion,
not the low proportion of a cell or tissue.
The central tenet of the mitochondrial theory
for aging is that those signals are reactive oxygen species (ROS), natural byproducts of mitochondrial respiration.6,7 The ensuing oxidative
damage mutates mtDNA, leading in turn to
even more ROS because of malfunctioning respiratory enzyme complexes, all of which, with
the exception of Complex II, contain protein
subunits encoded within mtDNA.8 The “vicious cycle” of ever increasing frequencies of
mtDNA mutations and oxidative damage ultimately causes cellular senescence, in part because of accruing oxidative damage and in part
because of declining mitochondrial oxidative
phosphorylation.9
We argue here that apoptotic signaling is the
primary pathogenic mechanism of mtDNA
mutations in aging. It is now well established
that mitochondria play a central role in amplifying cellular apoptotic signals within the intrinsic pathway for apoptosis.10 It is within mitochondrial membranes where interactions
take place among pro- and anti-apoptotic proteins such as Bak, Bax, and Bcl2 to regulate
outer membrane permeabilization and cytochrome c release, unleashing the caspase cascade culminating in apoptosis.11 We propose
that mutant mitochondrially encoded proteins
tap into that machinery already in place so as
to originate apoptotic signals. At any one moment, most cells sensing those signals suppress
execution of apoptosis by up-regulation of anti-

apoptotic proteins. Nevertheless, some cells
succumb. Finally, we will present a hypothesis
bearing on the molecular mechanism(s) for
how mutant proteins might originate apoptotic
signaling—a process we view as a mitochondrial misfolded protein response.

LITERATURE REVIEW
Transgenic mice with accelerated accumulation of
mtDNA mutations
In order to fully develop this hypothesis, we
will review recent results from a mouse model
that accumulates mitochondrial DNA mutations at an accelerated rate. Transgenic mice
were generated that accelerate accumulation of
mtDNA mutations specifically in the heart because of the expression of a proof-reading deficient pol g, the mtDNA polymerase.12 Since
the a-myosin heavy chain promoter driving
expression of the transgene turns on only
after birth, developmental abnormalities are
avoided which might otherwise arise from fetal expression of the transgene. Likewise, since
expression is restricted to cardiomyocytes,
pathogenesis in the heart is not complicated by
dysfunction in other organ systems, which
could impact on cardiac function. This potentially confounding situation is of course inherent to characterizations of aged versus young
animals or individuals. Similar interpretive difficulties are present with the recently reported
knockin mouse where the wild-type pol g has
been replaced by a proof-reading deficient version.13,14 In that model, mtDNA mutations are
generated in all tissues, presumably from early
embryogenesis onwards, it is more difficult to
distinguish pathology arising directly from
mtDNA mutations within a specific tissue from
pathology secondary to homeostatic imbalances in the animal.
In our transgenic mice, mtDNA mutations
rapidly accumulate specifically in the heart
from birth onwards. By 1 month of age, point
mutations reach levels of one per 10,000 bp of
mtDNA, determined by DNA sequencing of
cloned fragments generated without PCR amplification. By 3 months of age, mutation frequencies climb to 1.5 per 10,000 bp, represent-
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ing on average two point mutations per
mtDNA molecule. Mutations are randomly
scattered around the mitochondrial genome
and 5–10-fold higher than in wild-type animals.
Humans and rodents also accumulate large
scale deletion mutations in mtDNA with
age.15,16 These transgenic mice do likewise.
Thus, at the DNA level these mice recapitulate,
albeit at an accelerated pace, features of
mtDNA mutations found in aging humans and
rodents.
Cardiac pathology is first observed in these
transgenic mice at about 1 month of age.17
Transgenic animals invariably develop a fourchamber dilated cardiomyopathy, atrial thrombosis, fibrosis, and histologically apparent cell
death.17 Conditions deteriorate over time so
that animals rarely live beyond 11/2 years of
age, with terminal signs and symptoms consistent with end-stage heart failure. Even at
younger ages (1–2 months) some animals develop congestive heart disease and experience
sudden death.
The severe pathology observed in these mice
seems to be inconsistent with the relatively benign frequencies of mtDNA mutations (i.e., ,1
mutation per 10,000 bp), raising concerns that
artifacts associated with the transgene may be
responsible for pathology, rather than the mutations themselves. Insertional mutagenesis of
a specific nuclear gene by the transgene itself
appears not to be involved since two independent lines show essentially identical phenotypes. Although transgene expression is some
2–4-fold higher than endogenous pol g in wildtype animals, transgenic animals expressing a
normal version of pol g at similar levels,
driven by the same a-MHC promoter, show no
cardiac pathology and no accumulation of
mtDNA mutations.17 DNA sequencing of the
entire transgene used for construction of transgenic mice, including sequences recovered by
PCR amplification from mouse chromosomal
DNA, show no second site alterations (unpublished data). In the transgenic heart, mtDNA
content does not differ from control littermates,
indicating minimal effects of the mutant proofreading domain on the catalytic property of the
enzyme.12 This is consistent with studies where
we showed that expression of the mutant versus wild-type transgene in cos cells yielded
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mtDNA polymerases with similar DNA synthetic activity, but as expected, the mutant enzyme lacked 39 exonuclease activity.12 Importantly, cardiac pathology in transgenic animals
correlates with the rise in the frequency of
mtDNA mutations rather than with expression
of the transgene. By day 2 after birth, transgene
expression is maximal, yet for the first 3–4
weeks of life cardiac structure appears to be
completely normal at the gross and histological level.17
Finally, we now better appreciate that a frequency of point mutations of about two per genome may not be so benign.18 As pointed out
in the Introduction, the aging human brain is
estimated to have about three point mutations
per genome, and this is considered a high burden. Similar to our mice, knockin mice expressing proof-reading deficient pol g in all tissues have point mutation frequencies in the
heart about 4–6-fold higher than wild-type controls.13,14 These mice similarly develop a dilated cardiomyopathy. What these mouse
models force us to face is that seemingly low
frequencies of randomly generated mtDNA
mutations are indeed pathogenic. They provide
a strong counterweight to those arguing that
the age-related rise in mtDNA mutations is an
epiphenomenon, not being high enough to
cause either disease or physiological senescence.19,20
No decreased respiration or increased
oxidative stress
We first tested the hypothesis that pathology
arose due to either decreased mitochondrial
respiration or increased oxidative stress. We focused on animals 1–2 months of age, when
pathology was first apparent so as to minimize
potential complications secondary to longstanding disease. No evidence was found for
either process.12,17,21 Specifically, with regards
to respiration:
1. By polarography, isolated mitochondria
from transgenic hearts showed no declines
in respiration rates or P:O ratios with a variety of substrates.12,17,21
2. Mitochondrial content of cytochromes was
normal.12,17,21

MITOCHONDRIAL DNA MUTATIONS AND APOPTOSIS

3. Specific activities of the cytochrome oxidase,
NADH-dehydrogenase, and ATP synthetase were normal17,21 (and unpublished
data).
4. Substrate driven increases in the transmembrane potential of isolated mitochondria
were normal.12,17,21
5. By western blotting, the content was normal
for cytochrome c and cox4, a mitochondrially encoded subunit of cytochrome oxidase.17
Furthermore, indirect evidence for a decline
in respiratory function was lacking. The content of ATP was not lower in the transgenic
heart; indeed, it was somewhat elevated.17 In
patients with mtDNA mutations high enough
to compromise oxidative phosphorylation,
compensatory responses up-regulate both mitochondrial gene expression and number.22 By
Northern blotting12,17,21 and electron microscopy,17 neither of those compensatory responses was seen in transgenic hearts. Indeed,
our collaborator performing the ultrastructural
analysis of tissue sections from 6-week-old animals could not distinguish transgenic from littermate controls when blinded to their identity.
Specifically with regards to oxidative stress:
1. No increases were seen in the transgenic heart
of either 8-OH-dG adducts in mtDNA or cellular and mitochondrial protein carbonyls,
both indicators of oxidative damage.21
2. Glutathione levels and the ratio of GSH/
GSSG were unaltered.21
3. Total and specific activities of mitochondrial
aconitase, an enzyme highly sensitive to oxidative damage, were normal.21
4. Upregulation of anti-oxidant defenses (e.g.,
copper/zinc superoxide dismutase, glutathione peroxidases) was not seen, either by
immunohistochemistry21 or by microarray
analysis.23
5. Activation was not seen of signaling pathways responsive to oxidative stress (e.g.,
MAPK, SAPK/JNK, NFkB [unpublished
data]).
6. Recent data from a separate model of increased mitochondrial DNA mutations in
the whole-animal confirm that there is no increased oxidative stress.14
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Collectively, the conclusion seems inescapable
that elevated frequencies of mtDNA mutations
in this model cause pathology by a mechanism
not directly related to disturbances in the function of the electron transport chain.
MtDNA mutations induce a pro-survival
response at the cellular level
At 1 month of age, when mice first show cardiac dilation, a surge of apoptosis occurs in the
heart so that, at its peak, about one in 50 cardiomyocytes are TUNEL positive.17 Histologically, degenerating cells and cell drop-outs are
visible by hematoxylin-eosin staining. Increased levels of cytosolic cytochrome c indicate mitochondrial involvement in the apoptotic signaling. But apoptosis wanes over the
ensuing weeks, so that by 8–10 weeks of age,
frequencies of TUNEL-positive cells are only
slightly higher than that of controls.17 Likewise,
cytosolic levels of cytochrome c decline but
remain still slightly greater than controls. The
decline in apoptosis correlates with a cellular
pro-survival response,17,24,25 a coordinated upregulation of multiple anti-apoptotic proteins,
including Bcl2, Bfl1, Bcl-XL, XIAP, and Hsp27,
which function to suppress programmed cell
death at various steps in the intrinsic pathway
of apoptosis.26,27 This pro-survival response persists for the life of the animal, possibly because
pro-apoptotic signaling persists, as evidenced
by cytochrome c release and mitochondrial associated Bax. Importantly, the pro-survival response occurs in all cardiomyocytes within the
heart, as shown by immunohistochemistry for
Bcl2 and Hsp27.17 It places the heart in a protective state against insults provoking cell
death,25 such as doxorubicin, a cardiotoxin that
causes apoptosis of cardiomyocytes.28
These results tell us that, at the cellular level,
increased frequencies of mtDNA mutations
provoke apoptotic signaling. Even at its peak,
however, levels of cytosolic cytochrome c in the
transgenic heart are less than 5% of the total,
suggesting that only a small fraction of mitochondria release cytochrome c at any one time.
This is consistent with cell culture studies indicating that cytochrome c release is an all-ornone phenomenon at the mitochondrial level.29
The implication is that it may not be the cellu-
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lar burden of mtDNA mutations per se that is
pathogenic, but rather either a threshold level
in some mitochondria or a specific mutation in
particular mitochondria. Since cardiomyocytes
contain thousands of mitochondria, each harboring several mtDNA molecules, some mitochondrion somewhere in the cell is bound to
harbor any specific mutation when the global
average of random mutations climbs to ,2 per
genome. The unfortunate few who have an
apoptosis-signaling mutation, however, have a
disproportionate effect on the entire population because of the cellular pro-survival response, which, for instance, places high levels
of Bcl2 on all mitochondria.25
It is the pro-survival response that represents
an important aspect of the pathogenesis of an
age-associated rise in mtDNA mutations. Bcl2
in the endoplasmic and sarcoplasmic reticulum
has been reported to alter permeability to calcium.30 Enforced over-expression of Bcl2 in the
mouse heart inhibits the mitochondrial sodium-calcium exchanger and inhibits opening
of the mitochondrial permeability transition
pore.31 Higher levels of Bcl-XL, Bfl1, XIAP,
Hsp27, and other participants in the pro-survival response would likewise be expected to
affect cellular functions. Thus, the pro-survival
response provoked by pro-apoptotic signaling
from a few mitochondria is one mechanism for
amplifying the pathogenic potential of a relatively low global average of mtDNA mutations
in a cell. At the moment, we do not know what
the molecular signaling pathways in cardiomyocytes are that up-regulate expression of
Bcl2 and other genes involved in the pro-survival response.
Cardiomyocytes in a pro-survival state have
enhanced physiological function
Is the pro-survival response acutely pathologic for cardiomyocytes? To address that question, we isolated single cells from dilated hearts
2–3 months of age and measured their contractility upon field stimulation at pacing frequencies of 0.5–4 Hz (Zhang et al., submitted). Surprisingly, transgenic cells have much greater
contractility than control cells, showing nearly
1.8-fold greater fractional shortening than con-
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trols at all pacing frequencies. Increased storage
of calcium in the sarcoplasmic reticulum and
increased release of calcium during the transient after electrical stimulation appear to play
an important role in that increased contractility. This hypercontractility indicates that transgenic cardiomyocytes are not physiologically
dysfunctional or senescent, despite having
higher levels of mtDNA mutations and despite
being in a pro-survival state. These results
seem paradoxical in that the heart is dilated
and diseased, yet the cells therein are functioning at a supraphysiological level. The resolution to that paradox rests in the observation
that, by 3 months of age, the transgenic heart
has about 45% fewer cardiomyocytes than littermate controls (Zhang et al., submitted). Presumably, this is a consequence of the low levels of persistent apoptosis in the transgenic
heart. Hypercontractility of the remaining cells,
then, is a compensatory response of the heart
to maintain cardiac output in the setting of a
much reduced cell number. Whether that hypercontractility response is mechanistically related to or independent of the pro-survival response is unknown at the moment.
These results provide a new framework for
viewing the pathogenesis of elevated levels of
mtDNA mutations in the heart with age. As
the burden of random mtDNA mutations
rises, a few mitochondria within a cell happen
to suffer the “right” mutation and initiate proapoptotic signaling. In cells with large numbers of mitochondria, such as cardiomyocytes,
eventually all cells are affected. Although a
vigorous anti-apoptotic, pro-survival response mostly suppresses execution of the
apoptotic command, some cells succumb nevertheless. However, new mtDNA mutations
continue to be generated with age, and the
burden of mtDNA mutations inexorably
climbs. Cells continue to be lost. The heart
compensates for the lost cells by up-regulating the physiological function of the remaining cells. But eventually in a post-mitotic organ that compensation is limited, leading to
either disease or physiological dysfunction at
the organ level. The evoked pro-survival response in the absence of cell death may also
by itself be maladaptive in the long term. This
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model, then, views apoptotic signaling as the
primary pathogenic mechanism for rising levels of mtDNA mutations.
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pathogenic, but because the pathogenic mutations are lost over time as cells die, leaving
behind those mutations with little or reduced
pathogenicity.

Role of ROS
In distinction to the free radical theory of aging, this model for the pathogenesis of an agerelated rise in mtDNA mutations does not
directly implicate generation of ROS as the primary mechanism for their pathogenicity. However, oxidative damage still plays an important
role. It is likely that in normal individuals oxidative damage is the main driving force for the
generation of mtDNA mutations in the first
place, resulting from the ROS generated by mitochondrial respiration. It would be interesting
to know whether the pro-survival response itself, or other cellular compensatory responses
that are invoked to maintain physiological
function of the organ, have direct effects on
ROS generation as well.
An apoptotic model for the pathogenesis of
mtDNA mutations has implications for research using model systems to study their effects. If only rare, “correct” mtDNA mutations generate mutant proteins capable of
interacting with the apoptotic machinery so
as to signal apoptosis, then those pathogenic
mutations would tend to be lost from a tissue
as it ages and cells die. A powerful strategy
to study the pathology of mtDNA mutations
that are present in aged or diseased tissues is
to fuse enucleated cells taken from such
donor tissues with recipient cells in culture
lacking mtDNA (i.e., rho0 cells).32 Even if the
pro-survival response mostly suppresses
apoptosis, allowing apoptosis-signaling mutations to persist longer than they would otherwise, cytoplasmic hybrids (cybrids) reconstituted with mitochondria from such tissues
may not invoke a pro-survival response, either at all or fast enough. Again, by the time
the cybrid cultures are established, the pathogenic mtDNA mutations might be lost. In an
ironic twist, those who argue that age-associated mtDNA mutations are an epiphenomenon—a consequence of aging but not its
cause—may be right. Not because mutagenesis of mtDNA is hardly high enough to be

Mitochondrial permeability transition pore as a
target for mtDNA mutations
This model then directs attention to how
mtDNA mutations, or more accurately mutant
mitochondrial proteins, originate apoptotic signaling (i.e., outer membrane permeabilization
and release of cytochrome c). One such target
may be the mitochondrial permeability transition pore (mPTP). This pore is a channel that
spans the mitochondrial inner and outer membranes and is thought to be comprised of a complex of proteins including the voltage dependent anion channel located in the outer
membrane and the adenine nucleotide translocator located in the inner membrane33 (for further complexities on the structure of the pore,
see others34,35). Pore opening breaks down the
osmotic barrier, which then leads to mitochondrial swelling, rupture of the outer membrane,
and cytochrome c release.36 Within the mitochondrial matrix, the activity of cyclophilin D
(CyP D) facilitates pore opening.37 Cyp D is a
chaperone having peptidyl-prolyl cis-trans isomerase activity and is the major cyclosporin A
(CsA) binding protein within mitochondria.38
CsA is a potent inhibitor of pore opening.39 In
rodent models for ischemic and traumatic brain
injury and cardiac injury following ischemiareperfusion, CsA treatment protects against
neuronal and myocytic cell death,40–42 suggesting that pore opening plays an important
role in the apoptosis observed in those models.
However, pore opening is not obligatory for cytochrome c release and apoptosis in all circumstances. Cells in culture can release cytochrome c and initiate apoptosis without pore
opening,43 reflecting perhaps the intrinsic ability of pro-apoptotic proteins such as Bak and
Bax to form channels within the outer membrane large enough for cytochrome c to escape.11,44,45
In order to determine if the pore is a target
for apoptotic signaling arising from mtDNA
mutations, we treated our transgenic mice with
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CsA starting at 3 weeks of age (before disease
is apparent) and continuing out to 6 weeks of
age (when disease is well established).46 CsA
treatment completely prevented the development of cardiac dilation. Mutation-induced
apoptosis was prevented, as was the induction
of the pro-survival response, as indicated by
the failure of Bcl2 to be up-regulated. Another
aspect of the cardiomyopathy in these transgenic mice is profound down-regulation of
the gap junction protein, connexin 43.46 CsA
treatment prevented that down-regulation as
well. Control animals treated with FK506
(which, like CsA, inhibits cytoplasmic calcineurin activity, an important regulator of myocytic function, but unlike CsA does not inhibit
mitochondrial Cyp D) showed none of the protective effects seen with CsA.46
These data implicate Cyp D function as necessary for the pathogenicity of elevated levels
of mtDNA mutations. Is that function its facilitation of mPTP opening, implying that mutant
mitochondrial proteins activate CyP D, so as to
potentiate pore opening? In the transgenic
heart, Cyp D is found associated with the mitochondrial inner membrane (unpublished
data), a feature that is linked with potentiation
of pore opening.47,48 Calcium overload is a potent trigger of pore opening,49 manifested in
vitro as a concentration-dependent dissipation
of the mitochondrial transmembrane potential.
Transgenic mitochondria show resistance to
pore opening (Mott et al., submitted). This resistance to pore opening is not what we would
have expected if mutant mitochondrial proteins potentiate pore opening, similar to, for example, the effects of oxidant treatment on isolated mitochondria.47,50
Further studies indicated that this resistance
is a consequence of the pro-survival response.
Bcl2 in mitochondrial membranes inhibits pore
opening.31,51 In our transgenic animals, resistance to pore opening correlates in time with
the up-regulation of Bcl2, which we know includes 5–10-fold higher levels of Bcl2 in mitochondrial membranes.25 Finally, pore opening
in transgenic mitochondria is normalized by
treatment with peptides whose sequences derive from the BH3 domains of Bax and Bid
(Mott et al., in preparation). Bax and Bid bind
Bcl2 through their BH3 domains,52 and pep-
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tides derived from those sequences interfere
with the ability of Bcl2 to protect against pore
opening and cytochrome c release.53,54 These
findings indicate that pore dysfunction in transgenic mitochondria is due to up-regulation of
Bcl2—and that pore dysfunction is one of the
consequences of the pro-survival response. They
suggest that potentiation of pore opening is not
the mechanism driving apoptotic signaling by
mutant mitochondrial proteins.
HYPOTHESIS
Molecular mechanism of apoptotic signaling by
mtDNA mutations
If it isn’t the pore, then what is the target for
mutant mitochondrial proteins? CsA treatment
of these animals strongly protects against development of disease and prevents apoptotic signaling. We suggest that it is inhibition of the
chaperone function of CyP D by CsA, not inhibition of its pore-opening function, that abrogates apoptotic signaling of mutant mitochondrial proteins. All mitochondrial-encoded proteins
are integral membrane subunits of the respiratory enzyme complexes, whose assembly and insertion into the inner membrane require the activity of chaperones.55 CyP D activity enhances
the kinetics of assembly,56,57 although its activity seems not to be essential, most elegantly demonstrated by the recent reports of CyP D null
mice in which mitochondrial function (aside
from pore opening) appears to be quite normal.58–60 Thus, inhibition of CyP D chaperone activity by CsA would be expected to at least delay the translocation of newly made mutant
mitochondrial proteins into the inner membrane.
Since misfolded mutant proteins within mitochondria are degraded more rapidly than their
wild-type counterparts,61–63 this delay by itself
may be sufficient to substantially reduce the levels of mutant proteins inserted into the mitochondrial inner membrane.
If inserted into the inner membrane, mutant
mitochondrial proteins would be poised to activate latent pro-apoptotic proteins. One such
candidate is Bak, a resident integral outer membrane protein, whose conformational activation
results in oligomerization, permeabilization of
the outer membrane, release of cytochrome c,
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and apoptosis.64 Since it is unlikely that simply
any mutant protein has the necessary structure
to interact appropriately with Bak, stochastic
mutagenesis of mtDNA would need to continue for some time so as to have a reasonable
probability of generating the appropriate mutant. Recall that we earlier suggested that it
may not be the burden of mutations per se that
triggers apoptosis with aging, but rather specific rare mutants. Thus, apoptotic signaling
may derive only from specific mutations in
some mitochondrial genes, perhaps only those
whose mutant protein product is situated
within the inner membrane in such a way so
as to be able to interact with Bak.

tributing to the high rates of atresia and apoptosis during oocyte development.65 Having
high sensitivity would help ensure that newborns are remarkably free of mutations.66 There
are likely additional safeguards in development that are beyond the scope of this review,
including a mitochondrial genetic bottleneck.67
Still, some mutations would bypass detection
by the mitochondrial misfolded protein response, as they would not result in misfolded
proteins (e.g., deletion mutations which completely inactivate mitochondrial translation).
Some potential examples of mutations that bypass selection are inherited mitochondrial
myopathies68 and common polymorphisms.69

Mitochondrial misfolded protein response

Testing the hypothesis

We term this postulated mechanism for
the pathogenicity of mutant mitochondrial proteins the mitochondrial misfolded protein
response. The hypothesis that misfolded mitochondrial proteins originate apoptotic signaling has several attractive features. First, the
level of misfolded proteins would be a sensitive indicator of stress. Remember the example
given in the Introduction of a cell with one mutation in a 1000; a respiratory decrease would
be all but undetectable. By detecting a positive
signal over a low background (misfolded proteins), the misfolded response would be sensitive to this low level of damage. Amplification
of its impact on cellular function would follow
from the pro-survival response. Further, the offending mutation would not be ignored
through the complementing gene product of
another mitochondrial genome in the same organelle. Another feature of this response system is that the insult need not necessarily derive from mtDNA mutations. Other stresses
can cause misfolding, including heat stress and
oxidative damage. In the case of oxidative
stress, it would be efficient to have a detector
of ROS in close proximity to a major generator
of ROS, the electron transport chain. Finally,
the sensitivity of the cellular response to misfolded proteins could be fine tuned to the demands of the cell via regulation by protective
proteins like Bcl2. So, for example, the maternal germ cell would be a cell where a low signal from mitochondria activates cell death, con-

This apoptotic model for the pathogenesis of
mtDNA mutations makes some testable predictions:
1. Pathology in mice expressing a proof-reading deficient pol g should be ameliorated
when the transgene is placed on a background null for CyP D or Bak. Null mice for
both of those proteins are available.59,70 Indeed, CyP D and Bak null mice, which by
themselves show remarkably little pathology, might show increased longevity since
the apoptotic pathogenicity of mtDNA mutations has been blunted.
2. Cybrids reconstituted with mitochondria
from aged tissues might reveal the apoptotic
potential of mtDNA mutations in the tissue
if the cybrid recipients over-express Bcl2 under control of a regulatable promoter. Once
established under high Bcl2 expression,
down-regulating Bcl2 in these cultures may
trigger a wave of apoptosis. The underlying
assumption here is that cells from aging tissues retain mitochondria with apoptotic signaling mutations because of up-regulation
of a pro-survival response.
3. Placing transgenic mice with rapid accumulation of mtDNA mutations on a Bcl2-deficient background should greatly increase
the pathogenicity of mtDNA mutations. Preliminary results with our transgenic mice indicate that this is indeed the case.
4. Finally, centenarians might exhibit poly-
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morphisms in the genes for CyP D or Bak
that result in reduced transduction of the
pathogenicity of mtDNA mutations.

CONCLUSION
It needs to be remembered that aging is a
complex, multifactorial process. This apoptotic
signaling hypothesis addresses the pathogenicity of only point mutations in mitochondrial protein genes. We know that point mutations in tRNA genes and massive deletion
mutations also accumulate with age, which
have the potential to completely prevent translation in affected mitochondria. Their pathogenicity would be expected to involve different mechanisms. In aging tissues, cells with a
heterogeneous spectrum of mutational types
and amounts are likely to be present resulting
in a complex interplay of pathologies. Our hypothesis hopefully will focus attention on
apoptotic signaling so as to better determine its
role in driving the aging process.
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